I20-I25 E65-E68 I10
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Participants 50-70 years of age, regardless of gender, who have not engaged in regular physical activity for at least one year and have hypertension (treated or untreated) and/or overweight/obesity (BMI = 28). The definition of little to no physical activity is based on an evaluation form also used in the ELITE trial and the 3F trial and means less than once a week of regular physical activity. Coronary angiographically confirmed coronary artery disease after infarction, stent implantation and/ or with bypass surgery no earlier than one year after qualifying event. Initial cardiac examination as recommended by the ESC. Signed informed consent must be obtained prior to the start of the survey
Exclusion criteria
Exclusion criteria: Age 70 years No confirmed coronary heart disease and/or no known coronary status Lack of medical fitness to play soccer (e.g. leg amputations, symptomatic PAOD with limitation of pain-free walking distance) Lack of informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main target criteria are:(Comparison before and at the end of the study after one year) a. The improvement of systolic and/or diastolic blood pressure of the casual blood pressure and in the ABDM (24h mean) and/ or the reduction of the number or dosage of antihypertensive drugs (definition: reduction of antihypertensive drugs: at least one substance class by at least half). b. Reduction of body weight c. Improvement of performance in spiroergometry | — |
Secondary
| Measure | Time frame |
|---|---|
| SECONDARY OBJECTIVE CRITERIA (In each case, comparison before and at the end of the study after one year). 1.Changes in cardio- and cerebrovascular risk factors: a. Average daily and nightly blood pressure (ABDM) b. Non-dipping, dipper, practice hypertension. c. Blood pressure variability (ABDM) d. Heart rate (day, night, variability) e. Adjustment of existing nicotine abuse f. Lowering LDL cholesterol and/or reducing lipid-lowering medications in number of substance class (at least 1) and/or reduction in dose (by at least half) g. Reduction of HbA1c and/or blood glucose-lowering drugs in number of substance class (at least 1) and/or reduction of dose (by at least half) in diabetes mellitus h. Changes in other laboratory findings 2. improvement of physical performance a. Increase in running performance in meters and/or decrease in mean heart rate during training (by Polar watches). b. Decrease in mean heart rate over 24h (by ABDM and Polar watches). c. Physical activity besides soccer training (Polar watch) d. Muscle strength (hd-EMG) 3. improvement of psychosocial factors: a. Improvement of depression (BDI II questionnaire) b. Improvement of occupational/private psychological stress (questionnaire). c. Improvement of well-being (SF-12 questionnaire) d. Nutrition (questionnaire) e. Brain performance (Demtect score). | — |
Countries
Germany
Contacts
Universitätsklinik für Kardiologie- Klinikum Oldenburg